Kazia Therapeutics (NASDAQ:KZIA) Stock Price Down 1.2% – Time to Sell?

Kazia Therapeutics Limited (NASDAQ:KZIA) traded down 1.2% during trading on Tuesday . The stock traded as low as $4.78 and last traded at $4.94. 32,132 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 415,323 shares. The stock had previously closed at $5.00.

Kazia Therapeutics Stock Down 1.2 %

The company has a 50 day moving average of $5.05 and a 200 day moving average of $4.05.

Institutional Investors Weigh In On Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. MAI Capital Management bought a new position in Kazia Therapeutics Limited (NASDAQ:KZIA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned about 51.66% of Kazia Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.